Avian Influenza

BioSante presents positive CaP-adjuvanted avian influenza vaccine data

Published in Vaccine Weekly, June 21st, 2006

BioSante Pharmaceuticals, Inc., (BPA) announced that Steve Bell, vice president of research and preclinical development, presented a case study highlighting the potential of BioVant, the company's calcium phosphate (CaP) nanoparticle-based vaccine adjuvant, in influenza virus vaccines, including H5N1 avian influenza, or bird flu.

The presentation took place at the Vaccine Discovery and Commercialization Conference in Philadelphia.

Bell provided an in-depth review of data presented earlier this month from three BioVant-adjuvanted flu vaccine preclinical studies using the M1 protein, H3N1 and H5N1 antigens. Results showed that BioVant effectively...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2006-06-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry